London. UK. 28 June 2011. A new report by visiongain, a London-based business information provider, predicts that the global biomarkers market will be worth $19.86bn in 2015. The market generated $14.18bn in 2010, according to Biomarkers: Technological and Commercial Outlook 2011-2021, published in June 2011.
A biomarker can be defined as a factor that can be measured with precision and that reflects a normal biological process or a therapeutic response. Biomarkers have great utility in the pharmaceutical industry as they can be used to deduce the pharmacokinetic-pharmacodynamic relationships of therapies as well as help in the determination of drug efficacy. This market has significant potential for growth because the utility of biomarkers spans all therapeutic areas and their use directly affects our ability to diagnose and monitor disease progression.
The report analyst says: "Accurate non-invasive methods for monitoring and quantifying the concentrations of biomarkers are vital for the early diagnosis of disease. At present, there is significant research activity in the discovery of novel biomarkers for a range of diseases. Over the course of the decade, the emphasis will gradually shift from biomarker discovery to biomarker validation. A key market driver will be patient stratification, especially for therapeutic areas such as oncology, where the disease is highly heterogeneous."
Visiongain's research suggests that the world biomarkers market will benefit from the manufacture of non-invasive methods for imaging biomarkers. The fields of genomics and proteomics will lead to new insights about disease mechanisms and facilitate the discovery of biomarkers.
Visiongain predicts that this market will grow steadily to 2021. The future of the biomarkers market looks promising. As the field of biomarker research matures, patient stratification will become routine. This new report complements visiongain's wide range of analytical reports in healthcare and other industries.
For sample pages of the report please visit http://www.visiongain.com/Report/632/Biomarkers-Technological-and-Commercial-Outlook-2011-2021
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 207 336 6100
ENDS
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100
About visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Pharmaceutical, Telecoms, Energy, Defence and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.